• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NameWAVELIGHT EX500 LASER SYSTEM
Classification Nameexcimer laser system
Generic Nameexcimer laser system
ApplicantALCON LABORATORIES, INC.
PMA NumberP020050
Supplement NumberS006
Date Received04/04/2011
Decision Date11/23/2011
Product Code
LZS[ Registered Establishments with LZS ]
Advisory Committee Ophthalmic
Supplement Typenormal 180 day track
Supplement Reason change design/components/specifications - component
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for increased pulse frequency from 400 to 500 hz, a new laser head, a new housing with greater integration of accessories, modified laser pulse temporal parameters, new eyetracker, new scanner, remodeled user interface, addition of networking capability, and modified software. The device, as modified, will be marketed under the trade name wavelight ex500 laser system and is indicated for laser assisted in situ keratomileusis (lasik) for: 1) the reduction or elimination of myopia of up to -12. 0 diopters (d) of sphere and up to - 6. 0 d of astigmatism at the spectacle plane in patients who are 18 years of age or older with documentation of a stable manifest refraction defined as <= 0. 50 d of preoperative spherical equivalent shift over one year prior to surgery; 2) the reduction or elimination of hyperopic refractive errors up to +6. 0 d of sphere with and without astigmatic refractive errors up to 5. 0 d at the spectacle plane, with a maximum manifest refraction spherical equivalent (mrse) of +6. 0 d in patients who are 18 years of age or older with documentation of stable manifest refraction defined as <= 0. 50 d of preoperative spherical equivalent shift over one year prior to surgery, exclusive of changes due to unmasking latent hyperopia; 3) the reduction or elimination of naturally occurring mixed astigmatism of up to 6. 00 d at the spectacle plane in patients who are 21 years of age or older with documentation of a stable manifest refraction defined as <= 0. 50 d preoperative spherical equivalent shift over one year prior to surgery; and 4) the wavefront-guided (wfg) reduction or elimination of up to -7. 00 d of spherical equivalent myopia or myopia with astigmatism, with up to -7. 00 d of spherical component and up to 3. 00 d of astigmatic component at the spectacle plane in patients who are 18 years of age or older with documentation of a stable manifest refraction defined as <= 0. 50 d of preoperative spherical shift over one year prior to surgery.
-
-